Can Adaptive Radiation Therapy Transform Head and Neck Cancer Care?
Publication Title: Will adaptive radiation therapy be the new state-of-the-ART in head and neck cancer?
Summary
- Question
- This editorial examines whether adaptive radiation therapy (ART) could become the standard approach in treating head and neck cancers. The authors specifically explored ART's potential to reduce radiation side effects, such as xerostomia (dry mouth caused by damage to salivary glands during radiation therapy), while maintaining effective tumor control.
- Why it Matters
- Head and neck cancers are often treated with radiation therapy, which can unintentionally damage nearby organs such as salivary glands, leading to side effects like xerostomia. This condition significantly affects patients’ quality of life, making it difficult to eat, speak, or sleep comfortably. ART builds upon advances like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) to further reduce side effects by adapting treatment plans to patients’ anatomy in real-time. If successful, ART could improve patient outcomes, minimize discomfort, and enhance overall quality of life while maintaining effective cancer treatment.
- Methods
- The authors reviewed findings from multiple clinical trials, including the DARTBOARD trial, which compared daily adaptive radiation therapy (DART) with conventional IGRT in 50 patients with head and neck squamous cell carcinoma (HNSCC). The study evaluated treatment toxicity, disease control, and patient-reported outcomes (PROs) over one to two years. DART involves adjusting radiation plans daily based on real-time imaging of patient anatomy, allowing for more precise targeting of tumors while sparing healthy tissue.
- Key Findings
- DART significantly reduced radiation exposure to critical organs, such as salivary glands, muscles involved in swallowing, and the skin, compared to IGRT. Patients in the DART arm experienced lower rates of acute dermatitis (skin irritation), but xerostomia outcomes did not differ significantly between the two groups. Both approaches showed excellent disease control, with similar survival rates and recurrence patterns. Importantly, no marginal recurrences were reported, indicating that tumor targeting remained accurate even with smaller treatment margins in the DART arm.
- Implications
- Although DART did not significantly improve xerostomia outcomes, the reduced exposure to radiation for nearby organs highlights its potential to minimize treatment-related side effects. This approach could be particularly beneficial for patients whose tumors are located near sensitive structures. The findings suggest that ART may represent an oncologically sound option for treating head and neck cancers, especially as technology advances to make real-time adaptation more feasible.
- Next Steps
- The authors suggest that future research should focus on identifying patient subgroups who may benefit most from ART based on tumor biology, geometry, and kinetics. They also emphasize the need for further trials to refine ART protocols and explore its integration with emerging technologies like artificial intelligence to streamline treatment adaptation.
- Funding Information
- This research was not funded. Yale University also provided funding and support for this research.
Full Citation
Rybkin A, Young M, Park H. Will adaptive radiation therapy be the new state-of-the-ART in head and neck cancer? Journal Of The National Cancer Institute 2025, 118: 1-3. PMID: 41066140, DOI: 10.1093/jnci/djaf283.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Alisa Rybkin, MD, MPH
First AuthorAssistant Professor of Therapeutic Radiology
Henry S. Park, MD, MPH
Last AuthorProfessor of Therapeutic Radiology